SAXENDA

This brand name is authorized in Nigeria. It is also authorized in Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Spain, Turkey, UK, United States.

Active ingredients

The drug SAXENDA contains one active pharmaceutical ingredient (API):

1	Liraglutide UNII 839I73S42A - LIRAGLUTIDE
	Liraglutide is a GLP-1 analogue with 97% sequence homology to human GLP-1 that binds to and activates the GLP-1 receptor. The GLP-1 receptor is the target for native GLP-1, an endogenous incretin hormone that potentiates glucose-dependent insulin secretion from the pancreatic beta cells. Unlike native GLP-1, liraglutide has a pharmacokinetic and pharmacodynamic profile in humans suitable for once daily administration.
	Read more about Liraglutide

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A6-100004	Solution for injection	Saxenda 6 mg/mL Solution for Injection in Pre-filled Pen INJ_SOL 6 mg/mL 3 mL x 3's (in Pre-filled pens)	Solution for injection Clear and colorless or almost colorless, isotonic solution; pH=8.15 10/30/2024 19:15:57 Saxenda 6 mg/ml solution for injection in pre-filled pen 1 ml of solution contains 6 mg of liraglutide. One pre-filled pen contains 18 mg liraglutide in 3 ml. A6-100004 Solution for injection intravenously or intramuscularly. 1 ml of solution contains 6 mg of Liraglutide One pre-filled pen contains 18 mg liraglutide in 3 ml. 3x3ml POM Novo Nordisk Pharma Ltd Nigeria 4th Floor GIL Group Buidling, 10, Gbolahan Lawal Close, Off Ashabi Cole Street, Alausa CBD, Ikeja, Lagos-Nigeria Novo Nordisk A/S Novo Nordisk A/S Novo Allé DK-2880 Bagsværd Denmark Denmark 09/10/2020 08/10/2025 No A10BJ02	09/10/2020

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SAXENDA Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A10BJ02	Liraglutide	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BJ Glucagon-like peptide-1 (GLP-1) analogues
Discover more medicines within A10BJ02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	526616060007907, 526616060008007, 526616060008107
CA	Health Products and Food Branch	02437899
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	211-MBE-0821
EE	Ravimiamet	1681017, 1681028, 1681039
ES	Centro de información online de medicamentos de la AEMPS	115992002, 115992003
FI	Lääkealan turvallisuus- ja kehittämiskeskus	513490
FR	Base de données publique des médicaments	61756418
GB	Medicines & Healthcare Products Regulatory Agency	337479, 383795, 385297
HK	Department of Health Drug Office	65010
IL	מִשְׂרַד הַבְּרִיאוּת	7758
IT	Agenzia del Farmaco	044018012, 044018024, 044018036
LT	Valstybinė vaistų kontrolės tarnyba	1076039, 1076040, 1076041
NG	Registered Drug Product Database	A6-100004
NL	Z-Index G-Standaard, PRK	151203
NZ	Medicines and Medical Devices Safety Authority	17703
PL	Rejestru Produktów Leczniczych	100342594
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67457001, W67457002, W67457003
SG	Health Sciences Authority	15338P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699676950157, 8699676950164, 8699676950171
US	FDA, National Drug Code	0169-2800, 50090-4257